| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 210,000 | $262.24 | $55,070,947.22 | - | +15.4% | +22.3% | |
| Mar 4, 2022 | ALKS Alkermes Plc. | Snyderman Nancy Lynn Md | Director | Buy | 427 | $23.43 | $10,004.61 | +4.8% | +28.3% | +17.6% | |
| Mar 4, 2022 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | President &CEO | Sell | 23,348 | $51.63 | $1,205,354.58 | -0.8% | +35.4% | +39.5% | |
| Mar 4, 2022 | LNTH Lantheus Holdings, Inc. | Marshall Robert J. Jr.53 | CFO And Treasurer | Sell | 2,570 | $49.98 | $128,456.31 | -1.7% | +35.4% | +39.5% | |
| Mar 4, 2022 | LNTH Lantheus Holdings, Inc. | Blanchfield Paul54 | Chief Commercial Officer | Sell | 3,914 | $49.98 | $195,633.46 | -4.7% | +35.4% | +39.5% | |
| Mar 4, 2022 | LNTH Lantheus Holdings, Inc. | Walker Carol | Senior Vice President, Quality | Sell | 1,536 | $49.98 | $76,773.89 | -1.8% | +35.4% | +39.5% | |
| Mar 4, 2022 | LNTH Lantheus Holdings, Inc. | Montagut Etienne51 | Chief Business Officer | Sell | 1,635 | $49.98 | $81,722.21 | -1.6% | +35.4% | +39.5% | |
| Mar 3, 2022 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $174.12 | $1,044,714.72 | -7.6% | +32.2% | +42.1% | |
| Mar 3, 2022 | PCRX Pacira Biosciences, Inc. | Longenecker John P Phd | Director | Sell | 7,000 | $71.74 | $502,145.00 | -27.1% | -11.4% | -41.3% | |
| Mar 3, 2022 | DVAX Dynavax Technologies Corp | Janssen Robert71 | Senior Vice President | Sell | 24,036 | $10.57 | $253,997.76 | -26.4% | +5.7% | -7.4% | |
| Mar 3, 2022 | DVAX Dynavax Technologies Corp | Spencer Ryan | CEO And Director | Sell | 83,108 | $10.56 | $877,923.21 | -14.7% | +5.7% | -7.4% | |
| Mar 3, 2022 | DVAX Dynavax Technologies Corp | Burgess Justin60 | Principal Accounting Officer | Sell | 21,490 | $10.58 | $227,364.20 | -58.2% | +5.7% | -7.4% | |
| Mar 3, 2022 | DVAX Dynavax Technologies Corp | Novack David F73 | President &COO | Sell | 41,862 | $10.57 | $442,481.34 | -19.1% | +5.7% | -7.4% | |
| Mar 2, 2022 | BHC Bausch Health Companies Inc. | Spurr Robert82 | U.s. President-pharma Business | Sell | 1,595 | $23.37 | $37,275.15 | -2.4% | -59.8% | -61.7% | |
| Mar 2, 2022 | HIMS Hims & Hers Health, Inc. | O'Keefe Lynne Chou | Director | Sell | 40,178 | $5.04 | $202,497.12 | -100% | -22.5% | +98.7% | |
| Mar 2, 2022 | BHC Bausch Health Companies Inc. | Gordon Joseph F77 | Pres&Co-head Bausch&Lomb/ Int'l | Sell | 11,077 | $23.37 | $258,869.49 | -9.9% | -59.8% | -61.7% | |
| Mar 2, 2022 | ELAN Elanco Animal Health Inc | Hoover R David50 | Director | Buy | 10,000 | $28.83 | $288,322.50 | +4.7% | -18.3% | -62.0% | |
| Mar 1, 2022 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 14,585 | $5.26 | $76,644.18 | -57.0% | -20.0% | +128.3% | |
| Mar 1, 2022 | COLL Collegium Pharmaceutical, Inc | Ciaffoni Joseph | President And CEO | Sell | 76,094 | $18.47 | $1,405,224.15 | -10.3% | -15.6% | +44.7% | |
| Mar 1, 2022 | ELAN Elanco Animal Health Inc | Anand Kapila K | Director | Buy | 1,000 | $28.48 | $28,479.00 | +3.8% | -18.1% | -61.1% | |
| Mar 1, 2022 | LLY Eli Lilly & Co | Jonsson Patrik | SVP&Pres, Lly Imm, Lly Usa&CCO | Sell | 675 | $247.56 | $167,103.00 | -2.1% | +26.1% | +27.1% | |
| Mar 1, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $27.27 | $13,635.15 | -0.6% | +35.4% | +33.3% | |
| Mar 1, 2022 | LLY Eli Lilly & Co | Runge Marschall S | Director | Buy | 202 | $246.78 | $49,849.56 | +1.3% | +26.1% | +27.1% | |
| Mar 1, 2022 | BCRX Biocryst Pharmaceuticals Inc | Jones Michael L74 | Exec. Director, Finance - Pao | Sell | 2,300 | $17.20 | $39,560.00 | -17.0% | -44.6% | -47.5% | |
| Mar 1, 2022 | PCRX Pacira Biosciences, Inc. | Pace Gary W66 | Director | Sell | 30,000 | $66.87 | $2,006,150.28 | -10.4% | -6.5% | -35.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.